Note: Ingredients listed on restricted chemical lists
EC/CAS
247-500-7/55965-84-9
Name of the chemical
Mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)
Concentration
<0.1
EC/CAS
220-239-6
Name of the chemical
Mixture of 5-Chloro-2-methyl-isothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one 2-Methyl-2H-isothiazol-3-one
Concentration
N/A
General Information
Version
3.0
Revision date
2022-02-18
Product name
LDH-LQ_R1
1.2.1 Relevant identified uses
Professional use
Emergency telephone
+34 972 690 800
Icons in SDS
Company Information
company name
SPINREACT, S.A.U.
e-mail address of the competent person responsible for the Safety Data Sheet
spinreact@spinreact.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H317, H319
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Contains
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7], and 2-methyl- 2H -isothiazol-3-one [EC no. 220-239-6] (3 1), reaction mass of 5-chloro-2-methyl-4- isothiazolin-3-one [EC no. 247-500-7], and 2-methyl-4-isothiazolin-3-one [EC no. 220-239-6] (3:1) (Proclin 300)
Hazard statements
H315 - Causes skin irritation. H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation.
Precautionary statements
P261 - Avoid breathing vapours. P264 - Wash hands thoroughly after handling. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.
Other hazards which do not result in classification
None under normal conditions. Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
